140
Participants
Start Date
May 16, 2018
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
BI-1206
"BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion"
Rituximab
Rituximab 375 mg/m2, as per SmPC
Acalabrutinib
Acalabrutinib 100 mg orally as per SmPC
ACTIVE_NOT_RECRUITING
Emory University Hospital, Atlanta
RECRUITING
Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405, Louisville
RECRUITING
Hospital São Rafael, Salvador
RECRUITING
Hospital de Clínicas de Porto Alegre, Porto Alegre
NOT_YET_RECRUITING
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba
NOT_YET_RECRUITING
Ruschel Medicina e Pesquisa Clínica, Rio de Janeiro
RECRUITING
A.C. Camargo Cancer Center, São Paulo
NOT_YET_RECRUITING
Hospital Amaral Carvalho, São Paulo
NOT_YET_RECRUITING
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo
RECRUITING
Hospital Israelita Albert Einstein, São Paulo
NOT_YET_RECRUITING
Hospital Samaritano, São Paulo
NOT_YET_RECRUITING
Hospital Sírio-Libanês, São Paulo
NOT_YET_RECRUITING
Krankenhaus Nordwest Klinik für Onkologie und Hämatologie, Frankfurt am Main
WITHDRAWN
Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care, Stuttgart
TERMINATED
Małopolskie Centrum Medyczne, Krakow
RECRUITING
Hospital ICO, Trias i Pujol, Badalona
RECRUITING
Hospital de la Santa Creu i Sant Pau, Dep Hematologia, Barcelona
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
RECRUITING
Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona
RECRUITING
Hospital General Universitario Gregorio Marañon-Oncología Médica, Madrid
RECRUITING
Hospital Universitario HM Sanchinarro, Madrid
RECRUITING
University Hospital Fundacion Jimenez Diaz, Madrid
NOT_YET_RECRUITING
Hospital Universitario Virgen de la Arrixaca, Murcia
RECRUITING
Hospital University Virgen Macarene, Seville
TERMINATED
Szpital Specjlistyczny, Grudziądz
TERMINATED
Department of Oncology, Skåne University Hospital, Lund
TERMINATED
Department of Oncology, Academical Hospital, Uppsala
Lead Sponsor
BioInvent International AB
INDUSTRY